The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review

HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer

(2023) Benjamin R. Lewis et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder

(2023) Franklin R. Schneier et al.   JOURNAL OF PSYCHIATRIC RESEARCH

Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial

(2023) Jordan Sloshower et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin’s effects on cognition and creativity: A scoping review

(2023) Justin N Bonnieux et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

(2022) Natalie Gukasyan et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms

(2022) Emma I Kopra et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report

(2022) Drummond E-Wen McCulloch et al.   Frontiers in Pharmacology

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

(2022) Guy M. Goodwin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder

(2022) Michael P. Bogenschutz et al.   JAMA Psychiatry

Psilocybin-assisted therapy improves psycho-social-spiritual well-being in cancer patients

(2022) Sarah Shnayder et al.   JOURNAL OF AFFECTIVE DISORDERS

Therapeutic use of psilocybin: Practical considerations for dosing and administration

(2022) Caroline A. MacCallum et al.   Frontiers in Psychiatry

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

(2022) Robin von Rotz et al.   EClinicalMedicine

Trial of Psilocybin versus Escitalopram for Depression

(2021) Robin Carhart-Harris et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Treatment resistance in psychiatry: state of the art and new directions

(2021) Oliver D. Howes et al.   MOLECULAR PSYCHIATRY

Serotonin toxicity of serotonergic psychedelics

(2021) Benjamin Malcolm et al.   PSYCHOPHARMACOLOGY

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

(2020) Gabrielle I Agin-Liebes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Pharmacological Treatments for Patients with Treatment-Resistant Depression

(2020) Valerie L. Ruberto et al.   Pharmaceuticals

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

(2020) Alan K. Davis et al.   JAMA Psychiatry

Hypertensive Emergencies

(2019) Latoya Brathwaite et al.   CARDIOLOGY CLINICS

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory

(2019) Leor Roseman et al.   JOURNAL OF PSYCHOPHARMACOLOGY

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Psychedelics and the essential importance of context

(2018) Robin L Carhart-Harris et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

(2018) Leor Roseman et al.   Frontiers in Pharmacology

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

(2017) R. L. Carhart-Harris et al.   PSYCHOPHARMACOLOGY

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

(2016) Theresa M Carbonaro et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms

(2016) Frederick S Barrett et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

(2016) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

(2016) Stephen Ross et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Alterations of consciousness and mystical-type experiences after acute LSD in humans

(2016) Matthias E. Liechti et al.   PSYCHOPHARMACOLOGY

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

Long-term follow-up of psilocybin-facilitated smoking cessation

(2016) Matthew W. Johnson et al.   AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

(2016) Jonathan AC Sterne et al.   BMJ-British Medical Journal

Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

(2015) Michael P Bogenschutz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

(2014) Matthew W Johnson et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

(2011) Roland R. Griffiths et al.   PSYCHOPHARMACOLOGY

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

(2010) Charles S. Grob et al.   ARCHIVES OF GENERAL PSYCHIATRY

Human hallucinogen research: guidelines for safety

(2008) MW Johnson et al.   JOURNAL OF PSYCHOPHARMACOLOGY